Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernesto Vigna

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Annals of Hematology|January 11, 2026
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?Francesco Tarantini, Corinne Contento, Ernesto Vigna, et al.
American Journal of Hematology|April 5, 2013
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Sonia Fabris, et al.
Hematological Oncology|May 31, 2022
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trialsEnrica Antonia Martino, Concetta Conticello, Elena Zamagni, et al.
Science Translational Medicine|February 16, 2018
Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolenceGiovanna Cutrona, Claudio Tripodo, Serena Matis, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica|July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Annals of Hematology|January 11, 2026
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?Francesco Tarantini, Corinne Contento, Ernesto Vigna, et al.
American Journal of Hematology|April 5, 2013
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Sonia Fabris, et al.
Hematological Oncology|May 31, 2022
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trialsEnrica Antonia Martino, Concetta Conticello, Elena Zamagni, et al.
Science Translational Medicine|February 16, 2018
Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolenceGiovanna Cutrona, Claudio Tripodo, Serena Matis, et al.
European Journal of Haematology|October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patientsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica|July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Pageof 12